Device founders often treat regulatory standing as a checkbox. A supplier either holds registration or does not, and the search moves on.

That reading leaves out the part that shapes a launch. Registration establishes eligibility rather than capability. What happens to a design between concept and first production lot shapes whether the program reaches market on schedule and within budget.

What Registration Actually Covers

An FDA registered medical device manufacturer has listed its facility and its device activities with the agency and accepts inspection against FDA quality system requirements. That standing is verifiable and worth confirming early.

It usually says less about execution than buyers assume. Registration records that the facility is on file with the agency for the activities it listed. It does not describe how the supplier handles a tolerance that cannot be held repeatably, or what happens when a validated design proves awkward to assemble.

Situations like those arrive on many programs. How a supplier responds to them tends to separate a smooth transfer from a stalled one.

The Gap Between a Working Prototype and a Buildable Device

A prototype proves the concept functions. Production asks a harder question: can this be built the same way, by different operators, across months of output.

Several gaps show up at that boundary.

1. Tolerances stacked too tightly. Dimensions that work on a machined prototype may not hold through an injection molding cycle at volume.
2. Features that resist inspection. A design that cannot be measured without disassembly can create quality problems nobody budgeted for.
3. Assembly sequences that depend on judgment. Steps requiring an operator to decide something tend to vary between shifts.
4. Components without qualified alternates. A single-source part can stall an entire validated build.
5. Materials chosen before processing was considered. A resin selected for performance may behave poorly in the mold.

Where Design for Manufacturability Earns Its Place

Medical device DFM review brings manufacturing engineers into the design conversation while changes remain inexpensive. The exercise asks a simple question of each feature: how will this be built, and how will anyone confirm it was built correctly?

Catching a draft angle problem during engineering costs a drawing revision. Catching the same problem after tooling is cut can cost a new tool, a fresh validation lot, and a revalidation cycle nobody planned around.

The timing matters more than the technique. Review that happens after design freeze tends to document problems rather than prevent them.

Documentation Travels With the Design

Design transfer moves more than geometry. The package that reaches production carries process parameters, inspection criteria, approved supplier records, and the reasoning behind material choices.

Gaps in that package surface later as questions nobody can answer. An operator asks why a step exists, and the person who knew has moved on. Rebuilding that reasoning after the fact usually takes longer than recording it the first time.

Suppliers who treat documentation as part of the deliverable, rather than paperwork completed afterward, tend to produce transfers that hold up under audit and under review by people who join the program later.

Questions That Reveal How a Supplier Works

Capability statements read alike across the industry. A few specific questions help separate them.

Does manufacturing input reach the design before tooling commitments, or after? Who owns the documentation package at release, and in what format? What happens when a validation lot reveals a process problem, and who absorbs the cost of the investigation?

Answers that arrive with examples attached usually indicate the supplier has worked through the situation before. Vague responses before a purchase order rarely sharpen afterward, and discovering that after tooling commitments is more expensive than asking early.

Choosing a Partner for a Multi-Year Program

Bringing a device to market is a multi-year commitment, and the supplier selected at prototype stage often carries the program into commercial production. That makes the selection worth more scrutiny than a capability comparison provides.

One useful signal is whether a supplier raises buildability concerns before being asked. A supplier that reviews a design and returns a list of questions is usually describing work it has done before.

DEM Manufacturing applies medical device DFM review during engineering, so buildability problems surface while corrections remain inexpensive. As a reliable, U.S.-based FDA registered medical device manufacturer with ISO 13485:2016 certification and in-house molding, electronics, and assembly, DEM supports Class I and Class II programs from first concept through production.